Literature DB >> 3126278

Metabolites of 6-[18F]fluoro-L-dopa in human blood.

G Firnau1, S Sood, R Chirakal, C Nahmias, E S Garnett.   

Abstract

The metabolites of 6-[18F]fluoro-L-dopa in the blood plasma of healthy humans have been identified as 3-O-sulfato-6[18F]fluoro-L-dopa, 3-O-methyl-6-[18F]fluoro-L-dopa, 6-[18F] fluorodopamine, and 6-[18F]fluorohomovanillic acid. The time course of these metabolites was followed up to 2 hr. The findings have implications for the use of 6-[18F]fluoro-L-dopa as tracer for cerebral dopamine metabolism. Despite the variety of metabolites in the peripheral blood there are only two 18F-carrying compounds, 6-[18F]fluoro-L-dopa and 3-O-methyl-6-[18F]fluoro-L-dopa, that can cross the blood-brain barrier. After 1 hr, the plasma concentration of 3-O-methyl-6-[18F]fluoro-L-dopa reaches approximately 20% that of 6-[18F]fluoro-L-dopa but the mean concentration of the O-methylated metabolite over the same interval is less than 5% that of 6-[18F]-fluoro-L-dopa.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3126278

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  7 in total

1.  A within-subject comparison of 6-[18F]fluoro-m-tyrosine and 6-[18F]fluoro-L-dopa in Parkinson's disease.

Authors:  Catherine L Gallagher; Bradley T Christian; James E Holden; Onofre T Dejesus; Robert J Nickles; Laura Buyan-Dent; Barbara B Bendlin; Sandra J Harding; Charles K Stone; Barb Mueller; Sterling C Johnson
Journal:  Mov Disord       Date:  2011-06-02       Impact factor: 10.338

Review 2.  Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease.

Authors:  S Kaakkola
Journal:  Drugs       Date:  2000-06       Impact factor: 9.546

3.  Anterior cingulate dopamine turnover and behavior change in Parkinson's disease.

Authors:  Catherine L Gallagher; Brian Bell; Matthew Palotti; Jen Oh; Bradley T Christian; Ozioma Okonkwo; Jitka Sojkova; Laura Buyan-Dent; Robert J Nickles; Sandra J Harding; Charles K Stone; Sterling C Johnson; James E Holden
Journal:  Brain Imaging Behav       Date:  2015-12       Impact factor: 3.978

4.  Assessment of dopamine metabolism in brain of patients with dementia by means of 18F-fluorodopa and PET.

Authors:  M Itoh; K Meguro; T Fujiwara; J Hatazawa; R Iwata; K Ishiwata; T Takahashi; T Ido; H Sasaki
Journal:  Ann Nucl Med       Date:  1994-11       Impact factor: 2.668

5.  Regional brain kinetics of 6-fluoro-(beta-11C)-L-dopa and (beta-11C)-L-dopa following COMT inhibition. A study in vivo using positron emission tomography.

Authors:  P Hartvig; K J Lindner; J Tedroff; P Bjurling; K Hörnfelt; B Långström
Journal:  J Neural Transm Gen Sect       Date:  1992

6.  Brain kinetics of L-[beta-11C]dopa in humans studied by positron emission tomography.

Authors:  P Hartvig; H Agren; L Reibring; J Tedroff; P Bjurling; T Kihlberg; B Långström
Journal:  J Neural Transm Gen Sect       Date:  1991

7.  Dopamine Synthesis Capacity is Associated with D2/3 Receptor Binding but Not Dopamine Release.

Authors:  Anne S Berry; Vyoma D Shah; Daniella J Furman; Robert L White; Suzanne L Baker; James P O'Neil; Mustafa Janabi; Mark D'Esposito; William J Jagust
Journal:  Neuropsychopharmacology       Date:  2017-08-17       Impact factor: 7.853

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.